Lilly regains an oncology asset in up-to-$575M AurKa deal by Amirah Al Idrus Monday, May 14, 2018 Eli Lilly is handing over $110 million up front for AurKa Pharma, regaining an asset it sold off in 2016.
Rapid Micro bags $60M to grow microbial detection business by Nick Paul Taylor Wednesday, May 2, 2018 The financing sets Rapid Micro up to support the growth of technology that automates the detection of microbes at drug production plants.
Centogene raises $28M to fuel expansion in the U.S. and China by Nick Paul Taylor Wednesday, June 14, 2017 Centogene has raised $28 million to expand its presence in the U.S. and China.
Neurimmune, TVM set up ALS biotech, secure Lilly support by Nick Paul Taylor Wednesday, December 7, 2016 Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis.
